stem cell technologies have facilitated the development of human cellular disease models that can be used to study pathogenesis and test therapeutic candidates. these models hold promise for complex neurological diseases such as alzheimer's disease (aD), because existing animal models have been unable to fully recapitulate all aspects of pathology. We recently reported the characterization of a novel 3D culture system that exhibits key events in aD pathogenesis, including extracellular aggregation of amyloid-b (ab) and accumulation of hyperphosphorylated tau. Here we provide instructions for the generation and analysis of 3D human neural cell cultures, including the production of genetically modified human neural progenitor cells (hnpcs) with familial aD mutations, the differentiation of the hnpcs in a 3D matrix and the analysis of aD pathogenesis. the 3D culture generation takes 1-2 d. the aggregation of ab is observed after 6 weeks of differentiation, followed by robust tau pathology after 10-14 weeks. brain-like environment rich in structural proteins such as laminin, entactin, collagen and heparan sulfate proteoglycans 28 . We confirmed that the 3D Matrigel serves as an excellent 3D seeding structure for Aβ aggregation once the aggregation is initiated, although it is still permeable to Aβ species. Moreover, previous studies suggested that 3D conditions that more closely mimic in vivo environments can accelerate neuronal differentiation and neural network formation 23, [29] [30] [31] [32] [33] [34] . Indeed, we found that 3D-differentiated ReN cells expressing FAD genes (FAD ReN cells) expressed higher levels of specific neural markers and elevated 4-repeat adult tau (4R tau) isoforms versus 2D conditions 14 .
IntroDuctIon
AD is the most common form of age-related dementia, and it is characterized by progressive memory loss and cognitive impairment. Familial, early-onset (<60 years), autosomal-dominant forms of AD (FAD) can be caused by mutations in the genes encoding amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) 1 . Sporadic AD typically presents at a later onset and is due to multifactorial genetic and environmental risk factors. The two pathological hallmarks of AD are extracellular amyloid plaques, which are mainly composed of Aβ peptides derived from APP via serial cleavage by β-and γ-secretase, and intracellular neurofibrillary tangles, which are composed of filamentous aggregation of hyperphosphorylated tau (p-tau) proteins 1 . It is hypothesized that the accumulation and aggregation of Aβ causes the formation of neurofibrillary tangles [2] [3] [4] [5] , but this has not been experimentally proven in any animal models. Only the models that overexpress frontotemporal dementiaassociated P301L MAPT (encoding microtubule-associated protein tau) mutant forms in addition to human APP and/or PSEN1 with FAD mutations develop both plaques and tangles, albeit in a disconnected manner [2] [3] [4] . Fundamental species-specific differences in genome and protein composition between humans and mice, such as the difference in number of tau isoforms, have precluded an accurate recapitulation of AD pathology.
Advances in the field of stem cell generation have further advanced the prospect of in vitro systems that model AD in human neurons, including the generation of induced pluripotent stem cells (iPSCs) from FAD patient fibroblasts [5] [6] [7] [8] [9] [10] . However, it has been challenging to replicate the aged AD brain environment in the presence of high levels of soluble and insoluble toxic Aβ species and thereby to realize full AD pathology [11] [12] [13] . Recently, we reported that genetically engineered human neural stem cells that overexpress FAD-related genes combined with a 3D culture condition induced robust AD pathogenesis, including extracellular aggregation of Aβ and accumulation of p-tau and aggregated tau as neurofibrillary tangles 14 . In this article, we describe our protocol for the generation of these 3D human neural culture models of AD, detail their technical background, describe the techniques we applied for their analysis and discuss their use and application.
Development of 3D human neural cell culture models of AD
We designed our AD model around two central technologies: hNPCs that produce high concentrations of pathogenic Aβ species and a Matrigel-based 3D culture system that provides an environment that favors Aβ deposition.
First, we engineered A FAD cell line that exhibits substantial amyloid pathology, and that can easily be maintained for several passages. We chose the immortalized hNPC cell line ReNcell VM (ReN) as a base for our platform because the cells can be maintained for more than 45 passages, are commercially available and can differentiate into neurons and glial cells with simple growth factor deprivation [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . The ReN cells were then transfected with internal ribosome entry site (IRES)-mediated polycistronic lentiviral vectors containing FAD-related genes encoding human APP with both the K670N/M671L (Swedish) and V717I (London) mutations (APPSL), PSEN1 with the ∆E9 mutation (PSEN1(∆E9)) and APPSL/PSEN1(∆E9) with either GFP or mCherry as a reporter for viral infection ( Figs. 1 and 2) . Fluorescence-activated cell sorting (FACS) was then used to enrich the population of cells with the highest expression levels ( Figs. 2 and 3) .
Second, we differentiated and maintained the FACS-sorted ReN cells expressing high levels of FAD genes in a 3D Matrigel culture system to promote extracellular deposition of Aβ ( Fig. 4 and Supplementary Fig. 1 ). We posited that, in 2D models, secreted Aβ may diffuse into the cell culture medium, disrupting aggregation, whereas the 3D Matrigel may prevent this diffusion of Aβ, allowing for high local concentrations that are sufficient to initiate aggregation. We chose Matrigel specifically as a 3D culture matrix because it can be easily solidified with ReN cells through moderate thermal change, and because it provides a brain-like environment rich in structural proteins such as laminin, entactin, collagen and heparan sulfate proteoglycans 28 . We confirmed that the 3D Matrigel serves as an excellent 3D seeding structure for Aβ aggregation once the aggregation is initiated, although it is still permeable to Aβ species. Moreover, previous studies suggested that 3D conditions that more closely mimic in vivo environments can accelerate neuronal differentiation and neural network formation 23, [29] [30] [31] [32] [33] [34] . Indeed, we found that 3D-differentiated ReN cells expressing FAD genes (FAD ReN cells) expressed higher levels of specific neural markers and elevated 4-repeat adult tau (4R tau) isoforms versus 2D conditions 14 .
Although the characteristics of the 3D culture system are essential for fully recapitulating AD, the same properties cause several technical difficulties in classical biochemical and imaging analyses. For immunofluorescence (IF) and fluorescence or confocal microscopy, we developed thin-layer cultures (~100-300 µm) that could be imaged at high magnification. For biochemical analyses that required higher concentrations of biomolecules, we differentiated cells into thick-layer cultures (~4 mm) (Fig. 2) . We confirmed that both thin-layer and thick-layer 3D cultures robustly differentiated into neurons and glia 14 .
Comparison with other AD iPSC models
Most iPSC-derived human neurons with either APP or PSEN1 FAD mutations exhibit substantial increases in Aβ42 levels as compared with control cells, consistent with previous findings in other model systems [5] [6] [7] [8] [9] [10] . Interestingly, increases in p-tau levels were reported in some of these models. Israel et al. 6 showed an approximately twofold increase in the p-tau/total tau ratio in AD neurons. Recently, Muratore et al. 10 showed that AD neurons harboring the APP V717I mutation also showed increases in p-tau and total tau levels; furthermore they demonstrated that abnormal elevation in tau levels could be decreased by treating with Aβ-specific antibodies. Another recent study determined that differentiated human neurons from people with Down's syndrome generated high levels of Aβ40 and 42 owing to an extra copy of the APP gene 7 . Interestingly, Down's syndrome neuronal cultures revealed intracellular and extracellular aggregates of Aβ42, as well as increases in p-tau levels, even in 2D culture conditions after extended differentiation periods (>90 d). However, these studies could not recapitulate either the robust extracellular aggregation of Aβ or the aggregated p-tau pathology that are evident in our 3D culture study. Limitations of 2D culture protocols and/or low Aβ42 levels may be responsible for the lack of robust AD pathology in the previously described studies using stem cell-derived neuronal cultures.
Applications and limitations of the protocol
As this model is, to our knowledge, the first human cellular model to comprehensively show Aβ-driven tauopathy, this protocol can now be used to examine many other central parts of AD pathogenesis in vitro, including the molecular mechanisms underlying the production of high concentrations of Aβ, the accumulation of extracellular Aβ, the deposition of Aβ aggregates, the hyperphosphorylation of tau and p-tau aggregation. These paths may lead to new diagnostic and prognostic biomarkers of AD. The model can also be used to test other genetic or environmental factors associated with AD, either in conjunction with the FAD-causing mutations used in this study or in place of them. The flexible scalability of the system also makes it ideal for use in larger-scale testing and drug screening. More generally, this protocol may also be applicable to other neurodegenerative diseases with genetic variations, and it may be especially suitable for diseases characterized by abnormal aggregation of misfolded proteins. However, it is important to note that although the 3D-differentiated ReN cells with FAD mutations have reproduced key events in the pathogenic cascade of AD, including Aβ deposition and p-tau accumulation/aggregation, they are not surrogate human brain systems. First, our 3D culture model lacks human microglia cells (data not shown) that have a crucial role in Aβ clearance, brain inflammation and synaptic and neuronal damage. Our 3D differentiation protocol is also not designed to model the specific brain regions that are most affected in AD-i.e., the hippocampus and specific cortices. Indeed, we found that 3D-differentiated ReN cells are composed of a heterogeneous cell population, expressing markers for GABAergic, glutamatergic and dopaminergic neurons, as well as astrocytes and oligodendrocytes 14 . The overexpression of AD-related genes with multiple FAD mutations may generally restrict the use of our model for the study of the early stages of the disease, in which Aβ gradually accumulates without robust increases in tau phosphorylation. Moreover, our model also characterizes the late stages of the disease, in which p-tau aggregation develops. Regardless, we believe that the model and techniques described in this protocol offer an exciting model for the AD field, especially given that plaque and tangle formation are the two major hallmarks of this disease. Moreover, the model provides a methodology for the potential development of human neural cell cultures for the study of other neurodegenerative diseases and a robust platform for finding new AD disease targets and therapeutics.
Although the 3D culture described in here is optimized for ReN cells, we have also confirmed that the same 3D culture condition can be applied for differentiating human iPSC-derived neural stem cells including It-NES cells 35, 36 (data not shown).
Experimental design Establishment of ReN cells highly expressing Ab (Steps 1-16).
This protocol is optimized for a commercially available human neural progenitor cell line (ReNcell VM, EMD Millipore), which is immortalized, well characterized and genetically stable after prolonged passaging (>45 passages) [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] . ReN cells were transfected with either CSCW-APP-GFP, CSCW-PSEN1(∆E9)-mCherry or CSCW-APP-IRES-PSEN1(∆E9)-IRES-mCherry alone or together (Figs. 1-4) . The FAD mutations APP (K670N/ M671L (Swedish) and V717I (London)) and PSEN1(∆E9) were chosen specifically because they cause high production of Aβ42 and Aβ40 and a high ratio of Aβ42/Aβ40. ReN cells with CSCW-IRES-GFP or CSCW-IRES-mCherry alone were also generated as a control. Other FAD mutations may be selected for further characterization or comparison. Other gene editing and overexpression strategies including electroporation, zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) or clustered regulatory interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas)-based RNA-guided DNA endonucleases could also be used [37] [38] [39] . The presence of Aβ aggregates and p-tau aggregates described herein may depend on the hNPC line, the passage number, the type of FAD mutations, the number of cells seeded and the proportion of enriched cells by FACS. Generally, we observed extracellular Aβ aggregates starting at 6 weeks of differentiation and robust p-tau accumulation after 10 weeks. We also observed that both Aβ aggregates and p-tau pathology were further elevated through 17 weeks, depending on the cell line ( Figs. 7-9 ).
Endpoint analysis of Ab and p-tau pathologies (Steps 35 and 36).
For the thin-layer 3D culture, we describe how to analyze Aβ and abnormal p-tau accumulation using IF staining and immunohistochemical analysis (Figs. 7 and 8), as previously shown 14 . As most of our FAD ReN cells express high levels of GFP and mCherry, the UV-compatible amyloid dye Amylo-Glo can be used for detecting Aβ aggregates in the thin-layer 3D culture ( Supplementary Fig. 2 ).
For thick-layer 3D culture, we describe biochemical extraction to show the accumulation of Aβ and p-tau species in both soluble and insoluble fractions. Specifically, for detecting Aβ aggregates, we recommend using Tris-buffered saline (TBS)/2% (wt/vol) SDS/formic acid serial extraction, whereas for detecting tau aggregation we recommend using a 1% (wt/vol) sarkosyl extraction method, as shown in Figure 9 . Accumulation of SDS-resistant Aβ oligomers, including dimers, trimers and tetramers, can also be used as indirect markers for Aβ aggregation. To monitor the proper 3D differentiation, analyze the expression of adult neural markers, including 4R tau, by using reverse-transcription PCR (RT-PCR), quantitative real-time-PCR (qRT-PCR) 14 and IF staining (as shown in Fig. 6 ). Lactate dehydrogenase (LDH) levels in 3D culture medium should also be measured routinely to detect the cell death rate in these cultures. 42 , and these are available through the MGH viral core (https://vectorcore.mgh.harvard.edu). CSCW-APP-GFP, CSCW-PSEN1(∆E9)-mCherry or CSCW-APP-IRES-PSEN1(∆E9)-IRESmCherry vectors (Fig. 1) were constructed by inserting full-length APP with FAD mutations APP (K670N/M671L (Swedish) and V717I (London)), PSEN1 with a FAD mutation or both APP and PSEN1 with the FAD mutations 14 . We have our lentiviral vectors packaged by our viral core, and then by the MGH viral core 14, 42 . To package lentiviral vectors, first generate lentiviral particles by co-transfecting 293T cells with plasmids, the lentivirus packaging genome CMVR∆8.91 and envelope coding plasmid (pVSV-G).
MaterIals

REAGENTS Production of FAD cells
Approximately, 48-72 h after transfection, collect the lentiviral particles, concentrate them by ultracentrifugation and titer (transducing units (TU)/ml) by real-time PCR using specific primers against woodchuck hepatitis post-transcriptional regulatory elements (WPREs), as previously described 42 .  crItIcal The aliquots of packaged viral particles can be stored at −80 °C for up to 1 year without a substantial loss of titer.
• 
ReN differentiation medium
To prepare 500 ml of medium, combine 484.5 ml of DMEM/F12 (Gibco/Life Technologies) with 0.5 ml of heparin (2 mg/ml stock, STEMCELL Technologies), 10 ml of B27 (Life Technologies) and 5 ml of 100× penicillin/streptomycin/amphotericin B (Lonza). The medium can be stored at 4 °C for 2-3 months. ReN proliferation medium To prepare 100 ml of medium, combine 100 ml of ReN differentiation medium with 80 µl of bFGF stock and 100 µl of EGF stock. Filter the medium after adding all the reagents.  crItIcal Medium with growth factors can be kept at 4 °C for several weeks, but use fresh medium if there is any noticeable decrease in cell growth rate.
Tris-borate-EDTA (TBE) electrophoresis buffer, 10×
Add 108 g of Tris, 55 g of boric acid and 7.425 g of EDTA into a beaker, fill it up to 1 liter with ddH 2 O and mix it to dissolve. The 10× TBE buffer is stable at least for 6 months at room temperature (~24 °C). TBS buffer, 10× To prepare 100 ml of buffer, dissolve 6.05 g of Tris and 8.76 g of NaCl in 80 ml of H 2 O. Adjust the pH to 7.5 with 1 M HCl, and make up the volume to 100 ml with H 2 O. The 10× TBS buffer is stable at least for 6 months at room temperature.
1× TBS/Tween 20 (TBST) buffer
To prepare 1 liter of buffer, add 100 ml of 10× TBS buffer and 2 ml of Tween 20, and make up the volume to 1 liter with H 2 O. The 1× TBST buffer is stable at least for 3 months at room temperature. Blocking/dilution solution for immunostaining To prepare 250 ml of blocking/dilution solution, add 2.5 g of BSA (Sigma-Aldrich), 5.63 g of glycine and 0.25 g of gelatin in 200 ml of TBST; heat the mixture at 55 °C for ~10 min to dissolve gelatin, add 10 ml of donkey serum (Sigma-Aldrich) and add TBST to make the final volume to 250 ml. Filter the blocking/dilution solution with a 0.4-µm filter unit (Gibco) and store the solution at 4 °C. The blocking/dilution solution can be stored at 4 °C for 2-3 months. Amylo-Glo working solution, 0.02× Add 2 µl of Amylo-Glo (100×) to 10 ml of 0.9% (wt/vol) NaCl. Freshly prepare the solution every time. Amylo-Glo working solution, 0.1× Add 10 µl of Amylo-Glo (100×) to 10 ml of 0.9% (wt/vol) NaCl. Freshly prepare the solution every time. Tris/EDTA buffer, 10× To prepare 100 ml of buffer, dissolve 6.05 g of Tris and 8.76 g of NaCl in 80 ml of H 2 O. Add 4 ml of 0.4 M EDTA (pH 7.4) and adjust the pH to 7.6 with 1 M HCl; bring the volume to 100 ml with H 2 O. The 10× Tris/EDTA buffer is stable at least for 6 months at room temperature. TBS extraction buffer, 1× To prepare 10 ml of buffer, mix 8.65 ml of distilled water (HPLC grade), 1 ml of 10× TBS buffer (pH 7.4), one tablet of protease inhibitor cocktail, 0.1 ml of NaVO 3 (1 M), 0.1 ml of NaF (1 M), 0.05 ml of 1,10-o-phenanthroline (PNT, 200 mM), 0.05 ml of PMSF (200 mM) and 0.05 ml of phosphatase inhibitor.  crItIcal Freshly prepare the working solution before use; 1-ml aliquots of the extraction buffer without phosphatase inhibitors can be stored at −80 °C for several months. TBS extraction buffer, 2× To prepare 10 ml of buffer, mix 7.5 ml of distilled water (HPLC grade), 2 ml of 10× TBS buffer (pH 7.4), two tablets of protease inhibitor cocktail, 0.1 ml of NaVO 3 (1 M), 0.1 ml of NaF (1 M), 0.1 ml of PNT (200 mM), 0.1 ml of PMSF (200 mM) and 0.1 ml of phosphatase inhibitor.  crItIcal Freshly prepare the working solution before use; 1-ml aliquots of the extraction buffer without phosphatase inhibitors can be stored at −80 °C for several months. SDS extraction buffer, 1× To prepare 10 ml of buffer, mix 1 ml of SDS solution (20% stock), 1 ml of 1% (vol/vol) Triton X-100 (10% stock), 4.5 ml of distilled water (HPLC grade), 1 ml of 10× TBS/EDTA buffer (pH 7.4), two tablets of protease inhibitor cocktail, 0.1 ml of NaVO 3 (1 M), 0.1 ml of NaF (1 M), 0.1 ml of PNT (200 mM), 0.1 ml of PMSF (200 mM) and 0.1 ml of phosphatase inhibitor (100×).  crItIcal Freshly prepare the working solution before use; 1-ml aliquots of the extraction buffer without phosphatase inhibitors can be stored at −80 °C for several months. SDS extraction buffer, 2× To prepare 10 ml of buffer, mix 2 ml of SDS solution (20% stock), 2 ml of 1% (vol/vol) Triton X-100 (10% stock), 4.5 ml of distilled water (HPLC grade), 1 ml of 10× TBS/EDTA buffer (pH 7.4), two tablets of protease inhibitor cocktail, 0.1 ml of NaVO 3 (1 M), 0.1 ml of NaF (1 M), 0.1 ml of PNT (200 mM  crItIcal Freshly prepare the working solution before use; 1-ml aliquots of the extraction buffer without phosphatase inhibitors can be stored at −20 °C for several months. High-salt extraction buffer To prepare 10 ml of buffer, mix 1 ml of 10× TBS, 0.47 g of NaCl, 0.01 ml of EGTA (1 M), 1 g of sucrose, one tablet of protease inhibitor cocktail, 0.1 ml of NaVO 3 (1 M), 0.1 ml of NaF (1 M), 0.1 ml of PNT (200 mM), 0.1 ml of PMSF (200 mM) and 0.1 ml of phosphatase inhibitor (100×). Make 10 ml with distilled water (HPLC grade).  crItIcal Freshly prepare the working solution before use; 1-ml aliquots of the extraction buffer without phosphatase inhibitors can be stored at −20 °C for several months. LDH assay reagent preparation By using a CytoTox-ONE assay kit, add 11 ml of assay buffer to each vial of substrate mix to prepare CytoTox-ONE reagent. The CytoTox-One reagent is stable for 6-8 weeks at −20 °C. EQUIPMENT SETUP Placing tissue culture inserts on 24-well plates for 3D thick-layer culture Sterilize the forceps under the biosafety hood using ethanol and UV radiation. Carefully place cell culture inserts into each well of a 24-well plate (Falcon) with the sterilized forceps.  crItIcal Always combine plates and inserts from the same manufacturer. 
3|
Incubate the cells in a 37 °C CO 2 incubator for 3-5 min, add 3 ml of prewarmed ReN proliferation medium and transfer the cell suspensions to a 15-ml sterile conical tube.
4|
Spin down the cells at 2,000g (Sorvall T6000B) for 3 min at room temperature, remove the supernatant and resuspend the cell pellet in 12 ml of ReN proliferation medium. 
10|
Validate the infection by microscopic detection of GFP and mCherry fluorescence and western blot analysis of overexpressed APPSL and PSEN1(∆E9). Typically, >50% of infected cells visibly express the fluorescent marker.  crItIcal step Western blot analysis of successfully transduced cell extracts will show a PSEN1(∆E9) band (~40 kDa) and increased bands of full-length APP (695 isoform, ~110 kDa) and its C-terminal fragment (10-12 kDa). Western blotting can also be used to detect the elevated soluble APP alpha (sAPPα) levels in the supernatant, as shown in Figure 5 .
? troublesHootInG  pause poInt The infected, validated cells can be frozen and stored in a liquid LN2 tank at least for 1 year before FACS analyses.
enrich high-expressing transgenic ren cells • tIMInG 2 h 11| Culture the transduced ReN cells until confluence is reached (a 95% confluent T25 flask yields ~2-3 × 10 6 cells).
Although the optimal total cell count depends on the infection efficiency, at least 2-3 × 10 6 successfully transduced cells should be available (when assayed by FACS analysis or fluorescence microscopy).
12| Detach the cells as described in Steps 1-4, but resuspend the cell pellets with 4 ml of D-PBS. Determine the cell number using an automated cell counter.
13| Spin down the cells briefly at 2,000g (Sorvall T6000B) at room temperature, remove the supernatant and resuspend the cell pellets in ice-cold sorting medium (1 ml per 10 7 cells) using a 1,000-µl pipette.  crItIcal step Cells have to be resuspended in at least 200 µl of cell sorting medium.
14|
To singularize the cells, aspirate the cell suspension with a 1,000-µl pipette, gently press the tip against a cell strainer mesh at a 90° angle and empty the pipette forcefully. In case of blockage, carefully move the pipette tip across the mesh while maintaining pressure. Collect the filtered suspension in a 15-ml centrifugation tube.  pause poInt The suspended cells can be stored on ice at least for 1 h before FACS sorting. 
15|
21|
Spray down an ice bucket with ethanol and expose it to UV radiation in a cell culture hood for ~20 min.
22| Place the ReN cell differentiation medium and Matrigel stock on ice.  crItIcal step Matrigel tends to solidify at >10 °C. Thaw it at 4 °C overnight and then keep it on ice until use.
23|
Remove the medium from the T25 flasks with aspirating pipettes. Be careful not to touch the cells with the pipettes; always use the vacuum on the noncell side.
24|
Wash the cells once with 3 ml of D-PBS per T25 flask, and then carefully remove it with the aspirating pipettes.
25|
Add 0.5 ml of Accutase into each flask, and incubate the cells at 37 °C for 3-5 min.
26|
Dislodge the cells by forcefully tapping the side of the flask until clumps of cells completely detach.
27|
Resuspend the cells with 3 ml of ReN differentiation medium and pipette it up and down inside the flask at least three times.
28|
Transfer the cell suspensions from all five T25 flasks into a 15-ml tube.
29|
Centrifuge the tube for 2 min at 2,000g (Sorvall T6000B) at room temperature.
30|
Remove the medium with aspirating pipettes.
31|
Resuspend the cell pellet in 2 ml of cold ReN differentiation medium and vortex for 10 s. Set the 15-ml tubes on ice.
32| Take a small aliquot of suspended cells and dilute 1:10 for cell counting (10 µl of suspension: 90 µl of differentiation medium).
33|
Count the cells using a cell counter slide; dilute the cells if needed (optimum concentration is ~2 × 10 7 cells per ml before adding Matrigel at a 1:1 ratio in the next steps).  crItIcal step It is desirable to achieve a high cell concentration at this stage. We have found that 1 × 10 7 cells per ml (after adding Matrigel at 1:1 ratio; see the Step 34) show robust Aβ and p-tau accumulation in biochemical analysis. ? troublesHootInG (vii) Differentiate 3D-plated cells for 4-17 weeks, depending on the experiments. Drug treatments should be done in the last 2 weeks before endpoint analyses.  crItIcal step As it is not easy to monitor the thick-layer culture under an optical microscope, it is important to perform a routine LDH release assay to check the status of the cultures (see Step 36N) . It is also strongly recommended to set up thin-layer 3D cultures from the same Matrigel/cell mixture to monitor the culture quality. (b) thin-layer 3D cultures (100-300-mm thickness) • tIMInG 1 h (i) Add cold Matrigel to the cell suspension on ice (1:1 (vol/vol) dilution). Make sure to chill the pipette tips first by pipetting cold differentiation medium back and forth before transferring Matrigel. For 96-well-plate thin-layer cultures, further dilute 1:1 Matrigel/cell mixture by adding five volumes of the cold ReN differentiation medium (1:11 dilution final), and vortex it for 30 s. The same dilution rate can be used for thin-layer 3D cultures in 8-well/16-well chambered cover-glass slides or MatTek glass-bottomed dishes. We also found that a small volume of 1:1 Matrigel/cell mixture can be directly loaded onto these glass-bottomed dishes and these quasi thin-layer cultures can be used for confocal IF analysis.  crItIcal step Each lot of Matrigel has a different protein concentration, and therefore it needs to be pretested. We generally test 1:10, 1:15 and 1:20 dilutions and pick the best dilution rate for each lot.
? troublesHootInG (ii) Plate 100 µl of the Matrigel/cell suspension mixture per well of a 96-well plate using prechilled pipettes. If a thicker 3D culture is desired, use two drops per well (160 µl using a multichannel pipette). A volume of 200 µl is recommended for eight-well chambered cover-glass slides and 300 µl for glass-bottomed dishes. (iii) Incubate the plates at 37 °C in a CO 2 incubator overnight. (iv) The next day, add two drops of prewarmed ReN differentiation medium to each well of the 96-well plates (160 µl using a multichannel pipette), 200 µl for eight-well chambered cover-glass slides and 300 µl for glass-bottomed dishes.
(iv) Add 350 µl of buffer RLT to the pellet and mix thoroughly by repeatedly pipetting up and down. Transfer the lysate into a QIAshredder spin column and centrifuge it at 12,900g (Beckman Coulter, cat. no. 367160) for 1 min at room temperature. (v) Perform RNA extraction according to the manufacturer's protocol using the RNeasy mini kit. Measure the RNA concentration using the NanoDrop 1000 spectrophotometer.  pause poInt The resulting pellet can be directly processed or stored at −80 °C for 6 months. (vii) Determine the threshold cycles of the each gene using the iCycler iQ software (Bio-Rad). Normalize gene expression levels against β-actin mRNA levels in each sample, and calculate the percentage changes using the 2 −∆∆CT method as previously described 43 . (c) qrt-pcr for 3r/4r tau • tIMInG 8 h (i) To prepare a master mix (one reaction) for 3R or 4R tau, add the components in the table into an RNase-free microcentrifuge tube and mix by pipetting. Scale up the volume of the master mixes according to the number of reactions to be performed. (vii) Determine the threshold cycles of each gene using the iCycler iQ software (Bio-Rad). Normalize gene expression levels against β-actin gene expression levels in each sample, and calculate the percentage changes using the 2 −∆∆CT method as previously described 43 . 
